Alexion Pharmaceuticals, Inc.

NASDAQ: ALXN
$113.57
+$1.27 (+1.1%)
Closing price July 6, 2020
Monday's top analyst upgrades, downgrades and initiations included Alexion, American Water Works, Apple, Schwab, Crowdstrike, FedEx, IBM, Microsoft, Nvidia, Ryanair and Tesla.
The December 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks increased.
The December 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Here are three Credit Suisse #1 Top Picks that are showing an implied upside of 50% or more for 2020 as of mid-December.
The November 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The November 15 short interest data has been compared with the previous report, and short interest in...
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in...
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Achillion Pharmaceuticals shares skyrocketed on Wednesday morning on news that the firm would be acquired by Alexion Pharmaceuticals.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The September 30 short interest data has been compared with the previous report, and short interest in...
The September 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.